for giardiasis, 1704t
for hookworm, 1704t
for pinworm, 1708
Mechlorethamine, 469t, 1979t, 1981t
for HL, 2041
Meclizine (Bonine), 468t, 975, 976t
Meclofenamate, 870t
Medroxyprogesterone (Progestins)
for endometriosis, 1021–1022
for polycystic ovary syndrome, 1012t
Medroxyprogesterone acetate, 947–948, 1033t
Mefloquine, 49, 1696, 1698t, 1701
for depressive disorders, 1815t
Mefoxin (see Cefoxitin)
Megestrol, 88
Melatonin, 1768, 1776
for sleep, 1861
Meloxicam, 870t, 887, 888t
Melphalan, 469t, 470t, 1979t, 1987, 1991t, 1995t, 2004, 2037t
for blood progenitor cell rescue, 2005
Memantine, 88
for Alzheimer’s disease, 2239
MEN 1 (see Multiple endocrine neoplasia type 1)
Menactra, 1359
Menest (see Esterified estrogen)
Meningitis, for sepsis, 2186t
Meningococcal conjugate vaccine (MCV4), 1368
Menthol, 1626
Menveo, 1359
Meperidine, 677, 677t (see also Opioids)
dosage of, 1199t
Mepivacaine, 1177t
Meradimate, 849t
Mercaptobenzothiazole, 822t
Mercaptopurine, 470t, 918t, 1996, 1996t, 2017
for ALL, 2017t
dosage, 2017–2018
for T-cell lymphomas, 2020t
Merem (see Meropenem)
Meropenem (Merem), 1326t
for CAPD-associated peritonitis, 1476t
for CNS infections, 1373t
for cystic fibrosis, 461t
dosing of, 1337t
for febrile neutropenia, 1562
for gram-negative bacillary meningitis, 1378
for meningitis, 1378
for skin and soft tissue infections, 1550
for UTI, 1497t
Mesalamine (Apriso; Asacol HD; Delzicol; Lialda; Pentasa), 520, 521t, 523, 523t
Mesalamine enema (Rowasa), 523t
Mesalamine suppository (Canasa), 523t
Mescaline, 1885
Mesna, 709, 1992–1993
Metaxalone, 1186t
Metformin, 644, 678, 980, 1137t (see also Biguanide)
adverse effects of, 1112
clinical use of, 1113
contraindications and precautions of, 1112–1113
for diabetes, 167
doses of, 1133
drug interactions, 1113
efficacy of, 1113
mechanism of action, 1112–1113
for PCOS, 1012
pharmacokinetics of, 1112
pharmacologic therapy with, 1132–1133
therapy, 1133
Methadone, 90–91, 1187t, 1906t (see also Opioids)
consensus recommendations for, 1203t
dosage of, 1201–1203, 1202t
for opioid dependence in pregnancy, 1880
for opioid withdrawalsyndrome, 1878, 1879
toxicity
monitoring, 1203
signs and symptoms, 1203
Methamphetamine, 434
for ADHD, 1868t
CNS stimulants, 1884
Methicillin, 692, 1548
for skin and soft tissue infections, 1548
Methicillin-resistant Staphylococcus aureus (MRSA), 1379
Methimazole (Tapazole), 1042, 1059t, 1062, 1064–1065
for thyroid storm, 1067
Methocarbamol, 1186t
for nocturnal leg cramps, 173
Methotrexate (MTX), 469t, 470t, 524, 628, 708, 712t, 713t, 881, 882, 884, 899, 901, 903, 904, 925,
928, 1978t, 1979, 1985–1986, 1991t, 1992, 1995–1996t, 1996, 2022
adverse effects of, 892–893
for ALL, 2017t
cytotoxic effects of, 2009–2010
dosage, 892, 2017–2018
and folate or folinic acid, 893
for inflammatory bowel disease, 521t, 754
interactions, 893
intrathecal, problems of, 2016
and liver biopsy, 893
neurotoxicity of, 1985t
and NSAIDs, 892–893
for ophthalmopathy, 1067
for osteosarcoma, 2008–2009
for psoriasis, 836t, 840
and pulmonary disorders, 893
for T-cell lymphomas, 2020t
teratogenic effects, 973t
Methyldopa, 157t, 984, 985t, 1261t, 2261t
for hypertension in pregnancy, 159
in patients with CKD, 617
for pregestational diabetes, 979
Methylergonovine maleate, 997, 997t
M
e
t
h
yl
p
h
e
n
i
d
a
t
e
,
1
7
7
8
fo
r
A
D
H
D
,
1
8
6
7
t
M
e
t
h
yl
p
r
e
d
n
i
s
o
l
o
n
e
,
6
9
6
,
7
2
1
,
7
2
5
,
7
2
8
,
7
3
8
,
9
2
5
,
9
2
8
inj
e
c
t
io
n
s
,
6
2
6
fo
r
N
V
P
,
9
7
6
t
M
e
t
h
yl
s
a
l
i
c
yl
a
t
e
,
1
1
8
7
t
M
e
t
h
yl
x
a
n
t
h
i
n
e
s
,
fo
r
a
p
n
e
a
,
2
1
8
9
M
e
t
i
p
r
a
n
o
l
o
l
(
O
p
t
i
p
r
a
n
o
l
o
l
)
,
1
1
5
1
M
e
t
o
c
l
o
p
r
a
m
i
d
e
(
R
e
g
l
a
n
)
,
4
1
,
4
7
2
t
,
1
2
6
1
t
,
2
1
6
3
,
2
1
6
3
t
fo
r
dia
b
e
t
e
s
,
1
1
4
5
fo
r
N
V
P
,
9
7
5
,
9
7
6
t
fo
r
P
O
N
V
,
4
7
8
t
p
r
o
kin
e
t
ic
a
g
e
nt
s
,
5
0
8
M
e
t
o
l
az
o
n
e
,
2
7
0
M
e
t
o
p
r
o
l
o
l
,
2
2
0
,
1
0
6
2
,
1
2
7
2
,
2
2
6
1
t
in
a
c
ut
e
s
e
tt
in
g
,
2
5
3
in
H
F
r
E
F
,
2
8
7
–
2
8
8
fo
r
M
I
,
2
5
3
M
e
t
o
p
r
o
l
o
l
s
u
c
c
i
n
a
t
e
,
2
5
8
in
hyp
e
r
t
e
n
s
io
n
,
1
5
9
t
M
e
t
o
p
r
o
l
o
l
t
a
rt
r
a
t
e
,
fo
r
h
yp
e
rt
e
n
s
i
o
n
,
1
5
9
t
,
2
5
3
M
e
t
r
o
n
i
d
az
o
l
e
,
4
9
3
–
4
9
4
t
,
4
9
6
,
5
3
1
,
9
4
2
t
,
1
3
7
0
,
1
7
0
6
,
2
1
5
2
a
dv
e
r
s
e
e
ffe
c
t
s
o
f,
1
5
2
7
fo
r
a
me
b
ic
id
e
s
,
1
7
0
3
t
fo
r
a
n
a
e
r
o
b
e
s
,
1
3
2
8
t
fo
r
b
a
c
t
e
r
ia
l
v
a
g
in
o
s
is
,
1
5
2
2
b
r
a
in
a
b
s
c
e
s
s
a
n
d
,
1
3
8
2
fo
r
B
V
,
9
9
5
fo
r
C
D
I
,
1
4
6
5
fo
r
c
h
o
r
io
a
mnio
nit
is
,
9
9
6
do
s
in
g
o
f,
1
3
3
7
t
fo
r
g
a
s
tr
o
int
e
s
t
in
a
l
in
fe
c
t
io
n
s
,
5
2
4
fo
r
g
ia
r
dia
s
is
,
1
7
0
4
t
,
1
7
0
7
fo
r
P
I
D
,
1
5
1
2
–
1
5
1
3
t
fo
r
s
e
p
s
is
,
2
1
8
6
t
fo
r
s
kin
a
n
d
s
o
ft
t
is
s
u
e
in
fe
c
t
io
n
s
,
1
5
5
0
fo
r
tr
ic
h
o
mo
nia
s
is
,
1
5
2
6–
1
5
2
7
,
1
7
0
5
t
M
e
x
i
l
e
t
i
n
e
,
1
9
0
6
t
M
e
x
o
ryl
S
X,
8
5
2
p. 2
3
0
7
p. 2
3
0
8
M
e
x
o
ryl
XL
,
8
5
2
M
i
b
e
fr
a
d
i
l
,
1
2
8
M
i
c
a
fu
n
g
i
n
,
1
6
2
4
t
,
1
6
2
5
a
dv
e
r
s
e
e
ffe
c
t
s
o
f,
1
3
3
4
t
M
i
c
o
n
az
o
l
e
,
1
5
2
5
t
,
1
6
2
4
t
M
i
c
r
o
n
i
z
e
d
p
r
o
g
e
s
t
e
r
o
n
e
(
P
r
o
m
e
t
ri
u
m
)
,
1
0
3
3
t
M
i
c
r
o
s
o
m
a
l
e
p
o
x
i
d
e
h
y
d
r
o
l
a
s
e
,
9
7
2
M
i
d
az
o
l
a
m
,
fo
r
p
e
d
i
a
t
ri
c
i
n
t
u
b
a
t
i
o
n
,
2
1
9
9
t
M
i
d
o
d
ri
n
e
,
5
4
4
a
dminis
tr
a
t
io
n
,
5
5
5
in
tr
e
a
tme
nt
o
f
I
D
H
,
6
5
7
Mifepristone, 914t
Miglitol, 1125, 1126
Milk of magnesia, 87
Milnacipran, 1194t
Milrinone, 271, 298–299, 2207t
for postoperative cardiac failure, 363t, 364–365
Minocycline, 828, 830, 882, 883, 942t, 1265, 1325t
Minoxidil (Loniten), 157t, 160, 336t
for BP, 339
for hypertensive urgency, 339–340
in patients with CKD, 617
Mipomersen
adverse effects, 129
clinical pearls, 129
drug interactions, 129
efficacy, 128
mechanism of action, 128
pharmacokinetics/pharmacodynamics, 128
place in therapy, 129
Mirabegron, 2252
Miralax, 534
Mirapex (see Pramipexole)
Mirena (see Levonorgestrel-releasing IUD)
Mirtazapine, 1245, 1739, 1827
for depressive disorders, 1819t, 1821t
for diabetes, 2226t
for sleep, 1861
Misoprostol, 483t, 989
enhance mucosal defense mechanisms, 486
and lactation, 1003t
for postpartum hemorrhage, 997, 997t
teratogenic effects, 973t
Mitomycin, 469t, 1978–1979t, 1987, 1991t, 1995t
Mitomycin-C, 1981t
Mitotane, 470t
Mitoxantrone, 469t, 1222, 1979t, 1988
adverse effects of, 1230–1231
monitoring required for, 1231t
for prostate cancer, 2095
MMF (see Mycophenolate mofetil (MMF))
MMR vaccine (see Measles, mumps, rubella (MMR) vaccine)
Modafinil, 942t, 1224, 1777–1779
for ADHD, 1871
Moexipril, in hypertension, 153t
Molindone, for schizophrenia, 1785, 1788
Mometasone/formoterol (Dulera), 396, 816
Mometasone furoate (Nasonex), 441t
for allergic rhinitis, 442
Monoamine oxidase-b inhibitors, 1261t
adverse effects, 1257
dosage of, 1257
for Parkinson’s disease, 1253, 1256–1257, 1264
Monoamine oxidase inhibitors (MAOIs), 1748
for anxiety disorders, 1748
for panic disorder, 1748
and sleep, 1774
Monobactams
adverse effects of, 1332t
for UTI, 1497t
Monocid (see Cefonicid)
Monoclonal antibodies, 1981, 1984
alemtuzumab, 723
basiliximab, 723
Montelukast (Singulair), 440t
MOPP, 2041
Moricizine, 323
Morphine, 677, 677t, 942t, 1178, 1187t, 2131t, 2198 (see also Opioids)
for ACS, 241t
dosage of, 1199t, 1202, 1202t
for end-of-life care, 88–89
for opioid dependence, 1881
for pediatric intubation, 2199t
Morphine sulfate, 248
Moxifloxacin (Avelox), 1326t
for aerobic gram-positive cocci, 1326t
for anaerobes, 1328t
for CNS infections, 1373t
dosing of, 1337t
for skin and soft tissue infections, 1549, 1552
for tuberculosis, 1430t
MPA (see Mycophenolic acid (MPA))
MRSA (see Methicillin-resistant Staphylococcus aureus (MRSA))
mTOR (see Mammalian target of rapamycin (mTOR))
MTX (see Methotrexate (MTX))
Mucous membrane spray (Zolpimist), 1767t
Multiple endocrine neoplasia type 1 (MEN 1), 501
Multitargeted tyrosine kinase inhibitors, 1989–1990
Multivitamins, 88
alcohol withdrawal, 1896
Mupirocin, 819
MVC (see Maraviroc (MVC))
Mycifradin (see Neomycin)
Mycophenolate mofetil (MMF), 626, 709, 712t, 713t, 928, 942t
for FSGS patients, 629
in liver transplantation, 738–739
and mycophenolate sodium, 721
therapy for Wegener granulomatosis, 628
Mycophenolic acid (MPA), 721
N
Nabilone (Cesamet), 472t, 1204
Nabumetone, 888t
NAC (see N-acetylcysteine (NAC))
N-acetyl-b-d-glucosaminidase, 461
N-acetylcysteine (NAC)
for acetaminophen toxicity, 80–82
antioxidant, 643
duration of therapy of, 81
efficacy of, 81
intravenous, 80
mo
nit
o
r
in
g
e
ffic
a
c
y
o
f,
8
1
o
r
a
l,
8
0–
8
1
in
p
r
e
gn
a
n
c
y
,
8
0
r
o
ut
e
o
f
a
dminis
tr
a
t
io
n
o
f,
8
0
t
o
x
ic
ity
fr
o
m
,
8
1
–
8
2
N
-
a
c
e
t
yl
g
l
u
c
o
s
a
m
i
n
e
,
1
9
9
0
N
-
a
c
e
t
yl
-
p
-
b
e
n
z
o
q
u
i
n
o
n
e
i
m
i
n
e
(
N
A
P
Q
I
)
,
7
9
N
a
d
o
l
o
l
,
1
2
7
1
t
N
a
d
r
o
p
a
ri
n
,
1
3
1
2
N
a
fa
r
e
l
i
n
(
S
y
n
a
r
e
l
)
,
1
0
2
0
t
,
1
0
2
1
N
a
fc
i
l
l
i
n
(
O
x
a
c
i
No comments:
Post a Comment
اكتب تعليق حول الموضوع